ReviewInflammopharmacology2026
Role and therapeutic potential of icariin in metabolic diseases.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metabolic diseases (MetDs), characterized by metabolic dysregulation leading to abnormal blood glucose, lipid, and uric acid levels, frequently result in organ damage, functional impairment, and multiple complications. These conditions severely compromise quality of life and increase mortality risk, constituting a major global health burden. Icariin (ICA), a major bioactive compound derived from Epimedium species, has demonstrated substantial therapeutic potential in the management of MetD. Accumulating evidence indicates that ICA exerts beneficial effects by improving insulin resistance and modulating oxidative stress, fibrosis, inflammatory responses, and lipid metabolism. Through these mechanisms, ICA influences the pathogenesis and progression of diabetes mellitus, osteoporosis, metabolic dysfunction-associated steatotic liver disease, obesity, and various metabolic disorders. This review provides a comprehensive summary of recent advances in the application of ICA for the management of MetD, focusing on its molecular mechanisms, clinical applications, and research prospects. The aim is to establish a solid foundation for optimizing the therapeutic use of ICA in the management of MetDs.
Indexed as
Identifiers
42113093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.